All In Biotech

Drug Trial Radar · NCT00808132

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

A Double-Blind, Randomized, Placebo And Active- Controlled Efficacy And Safety Study Of The Effects Of Bazedoxifene/Conjugated Estrogens Combinations On Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women

Last checked: Nov 19, 2026Latest source record: Apr 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,886 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,886

Actual

Start

Jan 2009

Primary completion

Feb 2011

Study completion Feb 2011

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 15, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 40 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to evaluate the safety and effectiveness of this investigational drug for the treatment of menopausal symptoms while protecting the endometrium (uterine lining) and preventing postmenopausal osteoporosis. Subject participation will last approximately 14.5 months.

Conditions

  • Menopause
  • Osteoporosis

Interventions

  • bazedoxifene 20 mg/ conjugated estrogens 0.45 mgDrug

    One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.

  • bazedoxifene 20 mg/ conjugated estrogens 0.625 mgDrug

    One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.

  • bazedoxifene 20 mgDrug

    One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.

  • conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mgDrug

    One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.

  • PlaceboDrug

    One capsule, placebo (over-encapsulated), once a day for one year.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Endometrial Hyperplasia at Month 12: Main StudyTime frame: Month 12
  2. Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12: Osteoporosis Sub-StudyTime frame: Baseline, Month 12

Locations

178 sites in 12 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Chandler, Arizona

  • Pfizer Investigational Site

    Glendale, Arizona

  • Pfizer Investigational Site

    Mesa, Arizona

  • Pfizer Investigational Site

    Peoria, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Scottsdale, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Little Rock, Arkansas

  • Pfizer Investigational Site

    Carmichael, California

  • Pfizer Investigational Site

    Sacramento, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Upland, California

  • Pfizer Investigational Site

    Vista, California

  • Pfizer Investigational Site

    Walnut Creek, California

  • Pfizer Investigational Site

    Colorado Springs, Colorado

  • Pfizer Investigational Site

    Colorado Springs, Colorado

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Lakewood, Colorado

  • Pfizer Investigational Site

    New London, Connecticut

  • Pfizer Investigational Site

    Boynton Beach, Florida

  • Pfizer Investigational Site

    Clearwater, Florida

  • Pfizer Investigational Site

    Crystal River, Florida

  • Pfizer Investigational Site

    Daytona Beach, Florida

  • Pfizer Investigational Site

    DeLand, Florida

  • Pfizer Investigational Site

    Fort Lauderdale, Florida

  • Pfizer Investigational Site

    Fort Lauderdale, Florida

  • Pfizer Investigational Site

    Fort Myers, Florida

  • Pfizer Investigational Site

    Lake Worth, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Miami Springs, Florida

  • Pfizer Investigational Site

    New Port Richey, Florida

  • Pfizer Investigational Site

    Pinellas Park, Florida

Showing 40 of 178 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.